YOUR BUSINESS AUTHORITY
Springfield, MO
Pfizer stock may be coming out of a pandemic slump, now that it's in pole position for a coronavirus vaccine.
This week, its stock jumped 8% and hit a 52-week high of nearly $42, before settling down some.
The question remains whether a vaccine development ultimately would have a significant impact on the pharmaceutical giant’s bottom line. A key factor is how many other companies are standing at the finish line with vaccines of their own.
Read more from Fortune.
Organizers hope to bolster client traffic to center city businesses.